TR201901977T4 - Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. - Google Patents

Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. Download PDF

Info

Publication number
TR201901977T4
TR201901977T4 TR2019/01977T TR201901977T TR201901977T4 TR 201901977 T4 TR201901977 T4 TR 201901977T4 TR 2019/01977 T TR2019/01977 T TR 2019/01977T TR 201901977 T TR201901977 T TR 201901977T TR 201901977 T4 TR201901977 T4 TR 201901977T4
Authority
TR
Turkey
Prior art keywords
methyl
receptor modulators
piperazine derivatives
cxcr3 receptor
cxcr3
Prior art date
Application number
TR2019/01977T
Other languages
English (en)
Inventor
Caroff Eva
Meyer Emmanuel
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of TR201901977T4 publication Critical patent/TR201901977T4/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Buluş R1 ve R'nin tarifnamede açıklandığı gibi olduğu Formül (I)'e ait bileşiklerle, bunların farmasötik olarak kabul edilebilir tuzlarıyla ve ilaçlar olarak, özellikle de CXCR3 reseptörünün modülatörleri olarak bu tür bileşiklerin kullanımı ile ilgilidir.
TR2019/01977T 2015-01-15 2016-01-14 Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri. TR201901977T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP2015050691 2015-01-15

Publications (1)

Publication Number Publication Date
TR201901977T4 true TR201901977T4 (tr) 2019-03-21

Family

ID=55129889

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2019/01977T TR201901977T4 (tr) 2015-01-15 2016-01-14 Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.

Country Status (16)

Country Link
US (1) US10047080B2 (tr)
EP (1) EP3256469B1 (tr)
JP (1) JP6595003B2 (tr)
KR (1) KR102568469B1 (tr)
CN (1) CN107207491B (tr)
AR (1) AR103399A1 (tr)
AU (1) AU2016207990B2 (tr)
BR (1) BR112017015116A2 (tr)
CA (1) CA2972954C (tr)
ES (1) ES2712727T3 (tr)
MX (1) MX2017009292A (tr)
PL (1) PL3256469T3 (tr)
RU (1) RU2706232C2 (tr)
TR (1) TR201901977T4 (tr)
TW (1) TWI698434B (tr)
WO (1) WO2016113346A1 (tr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201600504TA (en) 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
CN107250133B (zh) 2015-01-15 2020-09-15 爱杜西亚药品有限公司 作为cxcr3受体调节剂的羟烷基哌嗪衍生物
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
WO2018011265A1 (en) * 2016-07-13 2018-01-18 Idorsia Pharmaceuticals Ltd Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators
CN110183388A (zh) * 2019-06-06 2019-08-30 常州合全药业有限公司 一种2-（1h-1,2,4-三氮唑-1-乙基）醋酸的合成方法

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002059107A1 (en) 2001-01-23 2002-08-01 Eli Lilly And Company Substituted piperidines/piperazines as melanocortin receptor agonists
DE60205727T2 (de) 2001-01-23 2006-06-29 Eli Lilly And Co., Indianapolis Piperazin- und piperidinderivate als agonisten des melanocortin-rezeptors
JP2004532838A (ja) 2001-03-02 2004-10-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモデュレーターとして有用な化合物及びそれを含む製薬組成物
JP4723242B2 (ja) 2002-06-12 2011-07-13 ケモセントリックス インコーポレーティッド 炎症および免疫障害治療用ｃｃｒ１アンタゴニストとして使用するための１−アリール−４−置換ピペラジン誘導体
US20050256130A1 (en) 2002-06-12 2005-11-17 Chemocentryx, Inc. Substituted piperazines
US7842693B2 (en) 2002-06-12 2010-11-30 Chemocentryx, Inc. Substituted piperazines
US7589199B2 (en) 2002-06-12 2009-09-15 Chemocentryx, Inc. Substituted piperazines
GB0315203D0 (en) 2003-06-28 2003-08-06 Celltech R&D Ltd Chemical compounds
WO2005035534A1 (ja) 2003-10-08 2005-04-21 Ono Pharmaceutical Co., Ltd. 複素ビシクロ環および複素トリシクロ環化合物およびその医薬
US20050124625A1 (en) 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050119252A1 (en) 2003-10-22 2005-06-02 Neurocrine Biosciences, Inc. Ligands of melanocortin receptors and compositions and methods related thereto
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
RU2006121990A (ru) 2003-11-21 2007-12-27 Эррэй Биофарма Инк. (Us) Ингибиторы протеинкиназ акт
US20060276465A1 (en) 2003-12-26 2006-12-07 Eisai R&D Management Co., Ltd. 1,2-di(cyclic) substituted benzene compounds
MY140489A (en) 2003-12-26 2009-12-31 Eisai R&D Man Co Ltd 1,2-di (cyclic) substituted benzene compounds
JP5046950B2 (ja) 2004-10-22 2012-10-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビター
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
CA2598457A1 (en) 2005-02-16 2006-08-24 Schering Corporation Pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity
CA2598456A1 (en) 2005-02-16 2006-08-24 Schering Corporation Heterocyclic substituted piperazines with cxcr3 antagonist activity
US7763616B2 (en) 2005-02-16 2010-07-27 Schering Corporation Piperazine-piperidines with CXCR3 antagonist activity
RU2007134260A (ru) 2005-02-16 2009-03-27 Шеринг Корпорейшн (US) Пиразинилзамещенные пиперазин-пиперидины с антагонистической активностью в отношении cxcr3
AU2006214480A1 (en) 2005-02-16 2006-08-24 Pharmacopeia, Inc. Novel heterocyclic substituted pyridine or phenyl compounds with CXCR3 antagonist activity
JP4688889B2 (ja) 2005-02-16 2011-05-25 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有する、アミン結合ピリジルおよびフェニルで置換されたピペラジン−ピペリジン
AU2006216941B2 (en) 2005-02-16 2009-12-03 Pharmacopeia, Llc Heteroaryl substituted pyrazinyl-piperazine-piperidines with CXCR3 antagonist activity
US7777035B2 (en) 2005-06-22 2010-08-17 Chemocentryx, Inc. Azaindazole compounds and methods of use
US20070010523A1 (en) 2005-06-22 2007-01-11 Chemocentryx, Inc. Azaindazole compounds and methods of use
WO2007002742A1 (en) 2005-06-28 2007-01-04 Pharmacopeia, Inc. Substituted [1,4]-diazepanes as cxcr3 antagonists and their use in the treatment of inflammatory disorders
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
TW200738701A (en) 2005-07-26 2007-10-16 Du Pont Fungicidal carboxamides
JP2009511582A (ja) 2005-10-11 2009-03-19 シェーリング コーポレイション Ｃｘｃｒ３拮抗薬活性を有する置換複素環式化合物
JP2009511628A (ja) 2005-10-18 2009-03-19 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｆｌｔ３キナーゼの阻害方法
WO2007064553A2 (en) * 2005-11-29 2007-06-07 Merck & Co., Inc. Thiazole derivatives as cxcr3 receptor modulators
US20100286191A1 (en) 2005-12-12 2010-11-11 Samuel Rachel G 2-Arylthiazole Derivatives as CXCR3 Receptor Modulators
WO2007076318A2 (en) 2005-12-21 2007-07-05 Smithkline Beecham Corporation Camphor-derived cxcr3 antagonists
WO2007100610A2 (en) 2006-02-23 2007-09-07 Merck & Co., Inc. Pyridine, pyrimidine and pyrazine derivatives as cxcr3 receptor modulators
JP2009530383A (ja) 2006-03-21 2009-08-27 シェーリング コーポレイション Ｃｘｃｒ３拮抗活性を有する、新規ヘテロ環ピリジン置換体
WO2007124369A2 (en) 2006-04-20 2007-11-01 Janssen Pharmaceutica N.V. Method of inhibiting c kit kinase
US7807671B2 (en) 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
FR2903405B1 (fr) 2006-07-04 2011-09-09 Pasteur Institut Composes a effet potentialisateur de l'activite de l'ethionamide et leurs applications
JP2009543782A (ja) 2006-07-14 2009-12-10 シェーリング コーポレイション Ｃｘｃｒ３アンタゴニスト活性を有している新規の複素環置換ピペラジン化合物
WO2008013622A2 (en) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Fungicidal azocyclic amides
MX2009006871A (es) 2006-12-22 2009-07-07 Schering Corp Compuestos heterociclicos con actividad antagonista de cxcr3.
WO2008091594A2 (en) 2007-01-24 2008-07-31 E. I. Du Pont De Nemours And Company Fungicidal mixtures
JP5337711B2 (ja) 2007-01-25 2013-11-06 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 殺菌性アミド
CA2695365A1 (en) 2007-08-03 2009-02-12 Schering Corporation Method of treating cxcr3 mediated diseases using heterocyclic substituted piperazines
TWI428091B (zh) 2007-10-23 2014-03-01 Du Pont 殺真菌劑混合物
EP2234971A1 (en) 2007-12-18 2010-10-06 Schering Corporation Process and intermediates for the synthesis of heterocyclic substituted piperazines with cxcr3 antagonist activity
AU2009206522B2 (en) 2008-01-25 2013-12-19 E. I. Du Pont De Nemours And Company Fungicidal amides
MX2010008102A (es) 2008-01-25 2010-08-04 Du Pont Compuestos fungicidas heterociclicos.
PE20091576A1 (es) 2008-02-19 2009-11-05 Sanofi Aventis DERIVADOS DE 3-(AMIDO O SULFAMIDO)-4-(4-AZINIL SUSTITUIDO)BENZAMIDA COMO INHIBIDORES DEL RECEPTOR DE QUIMIOQUINAS CxCR3
KR20100135952A (ko) 2008-04-30 2010-12-27 바이엘 크롭사이언스 아게 식물 보호제로서의 티아졸-4-카복실산 에스테르 및 티오에스테르
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
KR20110067052A (ko) 2008-10-01 2011-06-20 바이엘 크롭사이언스 아게 식물 보호제로서의 헤테로사이클릴 치환된 티아졸
KR101052065B1 (ko) 2008-10-15 2011-07-27 한국과학기술연구원 칼슘이온 채널 조절제로서 유효한 피라졸릴메틸아민-피페라진 유도체와 이의 제조방법
PL2358709T3 (pl) 2008-12-02 2014-06-30 Du Pont Grzybobójcze związki heterocykliczne
MX2011006042A (es) 2008-12-11 2011-07-04 Bayer Cropscience Ag Tiazoliloximeteres y tiazolilhidrazonas como agentes fitosanitarios.
US8362249B2 (en) * 2009-04-27 2013-01-29 Boehringer Ingelheim International Gmbh CXCR3 receptor antagonists
WO2010126811A1 (en) 2009-04-27 2010-11-04 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
EP2272846A1 (de) 2009-06-23 2011-01-12 Bayer CropScience AG Thiazolylpiperidin Derivate als Fungizide
UA107938C2 (en) 2009-08-12 2015-03-10 Syngenta Participations Ag Heterocycles with microbicidal properties
MX2012001690A (es) 2009-08-12 2012-02-22 Syngenta Participations Ag Heterociclos microbicidas.
WO2011051243A1 (en) 2009-10-29 2011-05-05 Bayer Cropscience Ag Active compound combinations
JP5827626B2 (ja) 2009-10-30 2015-12-02 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ ヘテロアリールピペリジン及びピペラジン誘導体
ES2553620T3 (es) 2009-12-21 2015-12-10 Bayer Cropscience Ag Bis(difluorometil)pirazoles como fungicidas
WO2011084985A1 (en) 2010-01-07 2011-07-14 Boehringer Ingelheim International Gmbh Cxcr3 receptor antagonists
CN102971314B (zh) 2010-04-28 2016-03-23 拜耳知识产权有限责任公司 酮基杂芳基哌啶和酮基杂芳基哌嗪衍生物作为杀菌剂
US8815775B2 (en) 2010-05-18 2014-08-26 Bayer Cropscience Ag Bis(difluoromethyl)pyrazoles as fungicides
BR112012026708A2 (pt) 2010-05-20 2015-09-22 Du Pont composto selecionado, composição fungicida e método para controlar doenças vegetais
BR112012030184A2 (pt) 2010-05-27 2015-12-29 Bayer Cropscience Ag derivados de ácido piridinilcarboxílico como fungicidas
US20120122928A1 (en) 2010-08-11 2012-05-17 Bayer Cropscience Ag Heteroarylpiperidine and -Piperazine Derivatives as Fungicides
US8759527B2 (en) 2010-08-25 2014-06-24 Bayer Cropscience Ag Heteroarylpiperidine and -piperazine derivatives as fungicides
MX352731B (es) 2010-10-27 2017-12-06 Bayer Ip Gmbh Derivados de heteroarilpiperidina y -piperazina como fungicidas.
BR112013012621A2 (pt) 2010-11-25 2016-07-12 Syngenta Participations Ag heterociclos microbicidas
US20130261154A1 (en) 2010-12-17 2013-10-03 E I Du Pont De Nemours And Company Fungicidal azocyclic amides
JP6326231B2 (ja) 2011-02-01 2018-05-16 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 殺菌剤としてのヘテロアリールピペリジン誘導体及びヘテロアリールピペラジン誘導体
BR112013020419A2 (pt) 2011-02-10 2016-07-12 Syngenta Participations Ag microbicidas derivados de pirazol
US8748432B2 (en) 2011-02-10 2014-06-10 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
BR112014005989B1 (pt) 2011-09-15 2019-11-05 Bayer Ip Gmbh compostos fungicidas piperidina-pirazoles, seus usos, método e composição para controlar fungos fitopatogênicos prejudiciais, e método para produzir composições
US20140243371A1 (en) 2011-10-18 2014-08-28 Syngenta Participations Ag Microbiocidal pyrazole derivatives
BR112014009037A2 (pt) 2011-10-18 2017-05-09 Syngenta Participations Ag derivados pirazol microbicidas
US8642774B2 (en) 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
EP2807153B1 (en) 2012-01-25 2020-03-25 Novartis AG Heterocyclic compounds and methods for their use
EA027595B1 (ru) * 2012-02-02 2017-08-31 Актелион Фармасьютиклз Лтд. 4-(бензоимидазол-2-ил)тиазольные соединения и родственные азапроизводные
WO2013127808A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2013127784A1 (en) 2012-03-02 2013-09-06 Syngenta Participations Ag Microbiocidal pyrazole derivatives
LT2855453T (lt) 2012-06-04 2017-02-27 Actelion Pharmaceuticals Ltd. Benzimidazolo prolino dariniai
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
WO2014075873A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
WO2014075874A1 (en) 2012-11-13 2014-05-22 Syngenta Participations Ag Microbiocidal pyrazole derivatives
CR20150364A (es) 2012-12-11 2016-09-20 Takeda Pharmaceuticals Co Compuesto heterociclico
JP6430494B2 (ja) 2013-06-24 2018-11-28 バイエル・クロップサイエンス・アクチェンゲゼルシャフト 殺真菌剤としてのピペリジンカルボン酸誘導体
SG11201600504TA (en) * 2013-07-22 2016-02-26 Actelion Pharmaceuticals Ltd 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives
WO2015026683A1 (en) 2013-08-22 2015-02-26 Merck Sharp & Dohme Corp. Compounds inhibiting leucine-rich repeat kinase enzyme activity
AR099789A1 (es) 2014-03-24 2016-08-17 Actelion Pharmaceuticals Ltd Derivados de 8-(piperazin-1-il)-1,2,3,4-tetrahidro-isoquinolina
AR102256A1 (es) 2014-10-15 2017-02-15 Actelion Pharmaceuticals Ltd Derivados biaromáticos básicos antibacterianos con sustitución de aminoalcoxi
CN107250133B (zh) 2015-01-15 2020-09-15 爱杜西亚药品有限公司 作为cxcr3受体调节剂的羟烷基哌嗪衍生物
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3

Also Published As

Publication number Publication date
CN107207491B (zh) 2020-08-25
CA2972954C (en) 2023-08-29
TWI698434B (zh) 2020-07-11
TW201632518A (zh) 2016-09-16
KR20170102355A (ko) 2017-09-08
EP3256469B1 (en) 2018-11-28
MX2017009292A (es) 2018-02-09
ES2712727T3 (es) 2019-05-14
CN107207491A (zh) 2017-09-26
RU2706232C2 (ru) 2019-11-15
AU2016207990B2 (en) 2020-01-30
AU2016207990A1 (en) 2017-08-31
CA2972954A1 (en) 2016-07-21
BR112017015116A2 (pt) 2018-04-10
AR103399A1 (es) 2017-05-10
PL3256469T3 (pl) 2019-05-31
KR102568469B1 (ko) 2023-08-18
US20180009800A1 (en) 2018-01-11
EP3256469A1 (en) 2017-12-20
RU2017128880A3 (tr) 2019-06-06
RU2017128880A (ru) 2019-02-15
JP6595003B2 (ja) 2019-10-23
JP2018502162A (ja) 2018-01-25
US10047080B2 (en) 2018-08-14
WO2016113346A1 (en) 2016-07-21

Similar Documents

Publication Publication Date Title
CY1122920T1 (el) ΑΛΑΤΑ ΠΑΡΑΓΩΓΩΝ 2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ-8-ΥΔΡΟΞΥΚΙΝΟΛΙΝ-2(1Η)-ΟΝΗΣ ΠΟΥ ΕΧΟΥΝ ΔΡΑΣΕΙΣ ΤΟΣΟ ΑΝΤΑΓΩΝΙΣΤΗ ΜΟΥΣΚΑΡΙΝΙΚΩΝ ΥΠΟΔΟΧΕΩΝ ΟΣΟ ΚΑΙ ΑΓΩΝΙΣΤΗ β2 ΑΔΡΕΝΕΡΓΙΚΩΝ ΥΠΟΔΟΧΕΩΝ
CY1118735T1 (el) Παραγωγα βενζιμιδαζολο-προλινης
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1119361T1 (el) 3,4-διυδροισοκινολιν-2(1h)-υλικες ενωσεις
TR201901977T4 (tr) Cxcr3 reseptörü modülatörleri olarak (r)-2-metil-piperazin türevleri.
CL2017001923A1 (es) Derivados de 9h-pirrolo-dipiridina
UY36056A (es) “compuestos de heteroarilo o arilo bicíclicos fusionados “.
NI201500119A (es) Compuestos de heteroarilo y sus usos
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
TR201900680T4 (tr) CXCR3 Reseptör modülatörleri olarak hidroksialkil- piperazin türevleri.
EA201691272A1 (ru) Тетрагидропиридопиразины в качестве модуляторов gpr6
EA201792374A1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA202091262A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
PH12015502632A1 (en) Cxcr7 receptor modulators
EA201400822A1 (ru) Производные гетероциклических амидов в качестве антагонистов p2xрецептора
TR201900659T4 (tr) Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
CL2017002498A1 (es) Piridopirimidinonas y su uso como modulares del receptor nmda
EA201600123A1 (ru) Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона
CY1120192T1 (el) Ενωσεις για την ενισχυση της γνωστικης λειτουργιας
EA201991045A1 (ru) Конденсированные азагетероциклические соединения и их применение в качестве модуляторов ampa-рецептора
MX2017013885A (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
EA202091403A1 (ru) Производные 2-оксо-1-пирролидинилимидазотиадиазола